ArticleESMO real world data and digital oncology2024

Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers.

S Pradervand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.